RoboSense Reached Strategic Partnership With Horizon Robotics to Accelerate Large-Scale Implementation of High-Level Autonomous Driving Solutions
23.12.2021 17:00:00 EET | Business Wire | Press release
RoboSense announced a strategic partnership with Horizon Robotics, a global pioneer in edge AI computing platforms. The two partners will mobilize their respective technological capacity and mass production experience to roll out in-depth cooperation focusing on advanced driver assistance systems (ADAS), autonomous driving, robotics, new intelligent transportation infrastructure and other applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211223005234/en/
Signing Ceremony (from left to right): Chunchao Qiu, co-founder and executive president of RoboSense; Dr. Chunxin Qiu, founder and CEO of RoboSense; Yi Shi, vice president of marketing of RoboSense; Xingyu Li, vice president of ecological development and strategic planning of Horizon Robotics; Dr. Kai Yu, founder and CEO of Horizon Robotics; and Dr. Jian Xu, chief ecological officer of Horizon Robotics (Photo: Business Wire)
Leveraging its leading smart LiDAR software and hardware technologies, RoboSense will join hands with Horizon Robotics to promote the large-scale commercialization of all segments of intelligent connected vehicle.
According to the partnership agreement, based on RoboSense’s second generation smart solid-state LiDAR RS-LiDAR-M1 (hereinafter referred to as "M1") and Horizon Robotics’ Journey 3 and Journey 5 automotive smart chips, the two companies will collaborate on the development and adaptation of integrated perception solutions for high-level autonomous driving pre-installed mass production. In the future, the partners will mobilize their respective advantageous industry resources to jointly promote the all-round standardized implementation of the domestic intelligent connected transportation industry.
Dr. Chunxin Qiu, founder and CEO of RoboSense:
" This strategic partnership will form a greater joint force and empower the two companies to create more visionary intelligent driving product solutions for the industry, to jointly build a prosperous ecology of the vehicle intelligence industry and advance the development of the intelligent connected transportation industry. "
Dr. Kai Yu, founder and CEO of Horizon Robotics:
" Through this strategic partnership, the two companies will fully complement each other with respective advantageous resources, jointly explore cutting-edge technologies and promote the mass production and large-scale implementation of pioneering intelligent driving solutions of the industry, leveraging technological innovation to build a safer and better smart mobility experience for the future. "
RoboSense is currently the only company in China to realize the automotive-grade domestic mass production of pre-installed LiDAR. Its second generation smart solid-state LiDAR, M1, has obtained pre-installed fixed-point project orders from multiple brands including GAC AION, WM Motor, ZEEKR, Lotus Cars, Inceptio and Zhito, covering models including passenger cars and commercial vehicles.
Horizon Robotics is a global leader in edge AI computing platforms based on the forward-looking concept of software and hardware integration As the only company in China to realize the automotive-grade domestic mass production of pre-installed AI chips, Horizon Robotics has reached intended partnership on priority mass production delivery with multiple car manufacturers including SAIC Motor, GWM, JAC Group, Changan Auto and BYD.
RoboSense and Horizon Robotics have a profound partnership history. The two companies announced intended partnership as early as 2019, and have been discussing and exploring innovations and integration solutions of vehicle intelligence technology, laying a solid foundation for the implementation of long-term and stable partnership achievements in the future.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211223005234/en/
Contact information
Grace Ye
RoboSense PR Manager
grace.ye@robosense.cn
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
euNetworks launches new quantum-safe private connectivity service powered by Adtran’s encrypted optical transport technology27.5.2026 11:00:00 EEST | Press release
Adtran and euNetworks today announced their collaboration on the launch of a new quantum-safe private connectivity service, Quantum Shield. euNetworks has developed Quantum Shield using Adtran’s optical transport technology to augment its broader architecture, which is designed to deliver secure, scalable data center connectivity across euNetworks’ pan-European network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526610601/en/ Adtran’s encrypted optical transport technology is helping euNetworks deliver the highest levels of protection for sensitive data moving across Europe. The new offering is built for enterprises with stringent security, performance and customer-controlled encryption requirements. The deployment combines high-capacity dedicated infrastructure with real-time fiber monitoring and enhanced optical-layer visibility to safeguard critical traffic. By integrating advanced encryption with continuous monito
National Bank of Greece in Cyprus Goes Live With Smartstream’s Air to Consolidate Reconciliations27.5.2026 10:55:00 EEST | Press release
Smartstream, the trusted data solutions provider for leading global financial institutions and enterprises, today announces that the National Bank of Greece (NBG) in Cyprus has successfully gone live with Air, the company’s AI-enabled reconciliation solution. The go-live marks a significant step forward in the bank’s operational efficiency, reducing daily manual processing effort and eliminating the complexity of working across multiple data formats. The bank has deployed Air’s Cash module, replacing both incumbent and consolidating four separate reconciliation systems for Instant, Cash, SEPA, and Nostro reconciliations, into a single, intelligent platform. Although transaction volumes were manageable, the fragmented landscape required significant daily manual effort to handle items individually across each system and to navigate multiple data formats. Following a market review, the bank committed to Smartstream’s Air, with self service model and AI-enabled automation being a distinct
Duco Launches the First Agentic Operations Platform for Financial Services27.5.2026 10:20:00 EEST | Press release
Duco, today launched the first agentic Operations platform for financial services. Built on the engine that already processes 20 billion transactions every month for more than 200 clients, including seven of the top 20 banks and ten of the top 20 asset managers, the platform brings together everything firms need to run post-trade Operations alongside autonomous agents, safely and at scale. The launch establishes a breakthrough the industry has been waiting for. A tool surface, purpose-built for agents. Duco has unbundled its platform into a new alternative agent layer that reconfigures its platform into hundreds of discrete capabilities servicing post trade. Model Context Protocol (MCP) gives capabilities covering reconciliation, data preparation, data access, audit trails, exception management, document creation and more. For the first time, agents have a verified, deterministic toolset built specifically for post-trade. Agents do not replace matching, rules or audit; they use them. P
Brenus Pharma Announces FDA Acceptance of IND Application for STC-1010 (BreAK-CRC001) in MSS Metastatic Colorectal Cancer (mCRC)27.5.2026 09:49:00 EEST | Press release
Brenus Pharma, a clinical stage biotechnology company developing novel in vivo immunotherapies for solid tumors, announced that the U.S. Food and Drug Administration (FDA) has accept the company's Investigational New Drug (IND) application for its first drug candidate, STC-1010, in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). STC-1010 is designed to address a critical unmet need worldwide. Approximately 95% of mCRC patients have MSS tumors, which demonstrate minimal response to standard immunotherapies. The FDA validated Brenus Pharma's advanced regulatory and manufacturing capabilities. This operational readiness will accelerate patient access and data generation across both European and US sites for a Phase II program planned for 2027. "FDA's acceptance of our IND represents a major validation of our program and enables the full execution of our clinical strategy across Europe and the United States. Achieving regulatory alignment across multiple jurisdictions refl
Alfasigma presents first data on filgotinib from the Phase 3 OLINGUITO trial in axial spondyloarthritis at EULAR 202627.5.2026 09:00:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare and specialty care where there is significant unmet patient need, presented positive results from the OLINGUITO Phase 3 clinical trial (NCT05785611iEudraCT 2022-501354-10-01ii) at EULAR 2026. In OLINGUITO filgotinib, an oral, once-daily JAK1 preferential inhibitor under investigation for the treatment of adult patients with active axial spondyloarthritis (axSpA), demonstrated sustained improvements in the signs and symptoms of axSpA, including disease activity and inflammation.iii Safety was consistent with the known profile of filgotinib, indicating a favourable benefit-risk profile for patients with active axSpA.iii The OLINGUITO trial consists of two international, randomised, double-blind, placebo-controlled studies (Study A and Study B), evaluating the efficacy and safety of filgotinib 200mg once-daily vs. placebo in patients with an established diagnosis of axSpA as per ASAS classification.i Eligi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom